Retrospective Cohort Study
Copyright ©The Author(s) 2023.
World J Clin Cases. Jan 6, 2023; 11(1): 104-115
Published online Jan 6, 2023. doi: 10.12998/wjcc.v11.i1.104
Table 1 Socio-demographics variables of participants (N = 262)
VariableNPercentage (%)
Gender
Female14153.8
Male12146.2
Age (mo)1
1-2410340.2
25-489135.5
49 and above6224.2
Screened for tuberculosis2
Yes24895.4
No124.6
Diagnosed to have tuberculosis3
Yes00
No260100.0
Type of Facility
Private for profit17366.0
Private not for profit8934.0
Table 2 Treatment monitoring

Variable
N
Percentage (%)
Commenced on isoniazidYes262100.0
1st mo WT (kg)1-7 238.8
8-1517065.4
16-23 6625.4
24-31 10.4
1st mo Dose< 100 mg10640.5
150-200 mg15358.4
250 mg and above31.1
2nd mo WT (kg)1-72311.4
8-1512260.4
16-235627.7
24-3110.5
2nd mo Dose< 100 mg8741.4
150-200 mg12157.6
250 mg and above21.0
3rd mo WT (kg)1-7157.9
8-1510555.3
16-236936.3
24-3110.5
3rd mo Dose< 100 mg7539.9
150-200 mg11159.0
250 mg and above21.1
4th mo WT (kg)1-7127.3
8-159255.8
16-235734.5
24-3142.4
4th mo Dose< 100 mg6738.5
150-200 mg10660.9
250 mg and above10.6
5th mo WT (kg)1-7106.3
8-159157.2
16-235333.3
24-3153.1
5th mo Dose< 100 mg6238.3
150-200 mg9961.1
250 mg and above10.6
6th mo WT (kg)1-764.1
8-157954.1
16-235638.4
24-3153.4
6th mo Dose< 100 mg5535.5
150-200 mg9963.9
250 mg and above10.6
Table 3 Determinant of treatment outcome, n (%)
Treatment Outcome
Completed
Loss to follow up
Total
χ2
DF
P value
GenderMale88 (33.6)53 (20.2)141 (53.8)1.33610.248
Female67 (25.6)54 (20.6)121 (46.2)
Total155 (59.2)107 (40.8)262 (100.0)
Age0-2457 (55.3)46 (44.7)103 (40.2)4.11420.128
25-4862 (68.1)29 (31.9)91 (35.5)
49 and above34 (54.8)28 (45.2)62 (24.2)
Total153 (59.8)103 (40.2)256 (100.0)
Type of facilityPFP103 (39.3)70 (26.7)173 (66.0)0.03010.862
PNFP52 (19.8)37 (14.1)89 (34.0)
Total155 (59.2)107 (40.8)262 (100.0)